Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Transplant Cell Ther. 2022 Mar 18;28(6):310–320. doi: 10.1016/j.jtct.2022.03.015

Table 2.

Cumulative Incidence of non-infectious pulmonary toxicity (NPT) after allogeneic transplantation

Outcomes N Probability (95% Confidence Interval)
Non-infectious pulmonary toxicity (IPS, DAH or COP) 21508
 3 months 4.0 (3.8–4.3)%
 6 months 5.9 (5.6–6.2)%
 1-year 8.1 (7.7–8.5)%
 3-year 10.3 (9.8–10.7)%
Idiopathic pneumonia syndrome (IPS) 21526
 3 months 2.6 (2.4–2.8)%
 6 months 3.8 (3.5–4)%
 1-year 4.9 (4.7–5.2)%
 3-year 5.8 (5.5–6.2)%
Diffuse alveolar hemorrhage (DAH) 21552
 3 months 1.4 (1.3–1.6)%
 6 months 1.8 (1.6–2)%
 1-year 2.1 (1.9–2.3)%
 3-year 2.3 (2.1–2.5)%
Cryptogenic organizing pneumonia (COP) 21553
 3 months 0.2 (0.1–0.2)%
 6 months 0.3 (0.3–0.4)%
 1-year 0.7 (0.6–0.8)%
 3-year 1.0 (0.8–1.1)%

NPT = non-infectious pulmonary toxicity; alloHCT = allogeneic hematopoietic cell transplantation